Evotec Acquires Bionamics GmbH to Accelerate "EVT Innovate" Strategy
March 24 2014 - 2:40AM
- Expanding discovery pipeline with portfolio of projects
especially in Multiple Sclerosis and CNS
- Appointment of Dr Timm Jessen as "EVP Business
Development EVT Innovate" to further enhance translation
capabilities
HAMBURG, Germany, March 24, 2014 (GLOBE NEWSWIRE) -- Evotec AG
(Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced the
acquisition of the Germany-based Bionamics GmbH. Bionamics is an
asset management company that focuses on the translation of
academic innovations into attractive assets for the biotech and
Pharma industry. The transaction comprises the acquisition of all
shares of Bionamics against cash and future milestone payments.
Next to an experienced management team Bionamics brings a portfolio
of highly attractive and fully funded projects especially in
neurodegeneration and CNS to Evotec.
Further financial details of the transaction remain
undisclosed.
Dr Werner Lanthaler, Chief Executive Officer of Evotec,
said: "With the acquisition of Bionamics we accelerate our
EVT Innovate strategy and enlarge our reach towards outstanding
innovations. We welcome the openness of Bionamics to join the
discovery infrastructure of Evotec. We are also very happy to
welcome Dr Timm Jessen back at Evotec. In his new management role,
Dr Jessen will be responsible for the commercialisation of "EVT
Innovate" projects."
Dr Timm Jessen, Managing Director of Bionamics GmbH,
commented: "We highly value Evotec's strategic
appreciation of our work and its success as demonstrated e.g. in
managing the NEU² programme, a consortium of academic, biotech and
Pharma partners focussing on novel products to treat Multiple
Sclerosis and other neurodegenerative diseases. The combination of
our management skills with Evotec's strong operational capabilities
offers a unique constellation for researchers and entrepreneurs
around the globe to accelerate their innovation together with us. I
very much look forward to expand this concept further within the
Evotec Group."
ABOUT BIONAMICS
Bionamics GmbH is an asset management company in Hamburg,
Germany, bridging the gap between excellent research projects and
the industry´s need for pre-clinical and clinical development
programmes. The company was founded in 2006 and currently employs
three employees. Bionamics has set up and manages NEU²
(www.neu-quadrat.de), a consortium established to generate new
treatment options in neurodegenerative diseases and supported by
public funds of up to EUR 40 Mio. Before founding Bionamics Timm
Jessen was the CSO of Evotec AG from 1997 to 2004.
ABOUT EVOTEC
AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the
Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim, MedImmune and
Andromeda in the field of diabetes, with Janssen Pharmaceuticals in
the field of depression and with Roche in the field of Alzheimer's
disease. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: Gabriele Hansen
Head of Corporate Communications
+49.(0)40.560 81-255
+49.(0)40.560 81-222 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Oct 2023 to Oct 2024